Kadmon (KDMN) Lifted to Buy at ValuEngine
ValuEngine upgraded shares of Kadmon (NYSE:KDMN) from a hold rating to a buy rating in a report released on Wednesday morning.
A number of other equities analysts also recently commented on the stock. WBB Securities upgraded shares of Kadmon from a sell rating to a hold rating and set a $2.90 price objective for the company in a research note on Wednesday, October 17th. Zacks Investment Research downgraded shares of Kadmon from a buy rating to a hold rating in a research note on Thursday, October 11th. Finally, HC Wainwright set a $25.00 price objective on shares of Kadmon and gave the stock a buy rating in a research note on Monday, August 13th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of Buy and an average target price of $11.43.
Shares of Kadmon stock traded down $0.05 during trading hours on Wednesday, reaching $2.64. 493,650 shares of the company’s stock were exchanged, compared to its average volume of 932,358. Kadmon has a fifty-two week low of $1.88 and a fifty-two week high of $5.86. The company has a market cap of $306.50 million, a price-to-earnings ratio of -1.86 and a beta of 3.57.
A number of large investors have recently modified their holdings of KDMN. BlackRock Inc. lifted its stake in Kadmon by 639.8% in the 1st quarter. BlackRock Inc. now owns 1,540,225 shares of the company’s stock valued at $6,546,000 after purchasing an additional 1,332,035 shares during the last quarter. Millennium Management LLC lifted its stake in Kadmon by 490.1% in the 1st quarter. Millennium Management LLC now owns 1,847,444 shares of the company’s stock valued at $7,852,000 after purchasing an additional 1,534,371 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Kadmon in the 1st quarter valued at about $106,000. Rhumbline Advisers acquired a new stake in Kadmon in the 2nd quarter valued at about $256,000. Finally, Bank of New York Mellon Corp lifted its stake in Kadmon by 191.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 198,063 shares of the company’s stock valued at $790,000 after purchasing an additional 130,096 shares during the last quarter. Institutional investors and hedge funds own 69.65% of the company’s stock.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Read More: NASDAQ Stock Market Explained
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.